Objective To investigate the clinical effect of programmed death protein-1(PD-1)inhibitor combined with craniocerebral radiotherapy in the treatment of non-small cell lung cancer(NSCLC)with brain metastases.Methods A total of 68 patients with brain metastases of NSCLC admitted to the 960th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army from September 2021 to May 2023 were selected and divided into two groups according to different treatment methods,among which the control group(n=33)was treated with systemic chemotherapy combined with cranial radiotherapy,and the observation group(n=35)was treated with systemic chemotherapy combined with cranial radiotherapy plus PD-1 inhibitors,and the two groups were treated with 4 courses of treatment,and the effi-cacy of the two groups was compared.Results The objective response rate(ORR)in the ob-servation group was higher than that in the control group(P＜0.05).After 4 courses of treat-ment,the level of tumor markers in the observation group was better than that in the control group(P＜0.05).The incidence of adverse reactions between the two groups was not signifi-cantly different(P＞0.05),and the 6-month survival rate of the observation group was 97.14％,higher than that of the control group(78.79％)(x2=3.886,P=0.049).Con-clusion Systemic chemotherapy plus PD-1 inhibitor combined with craniocerebral radiotherapy for NSCLC patients with brain metastases can significantly improve tumor markers,with good drug safety and high 6-month survival rate,which is worthy of promotion.
关键词
程序性死亡蛋白抑制剂/颅脑放疗/非小细胞肺癌/脑转移
Key words
programmed death protein inhibitor/craniocerebral radiotherapy/non-small cell lung cancer/brain metastases
维普
万方数据